A new eBook explores how using real world data from patients can help drug developers improve outcomes for non-small cell lung cancer and other patient populations.
As RWE continues to influence the future of drug development, pharma companies will inevitably encounter hurdles. But with the right approach, they can be overcome to unlock critical insights and bring better therapies to patients faster.
How to turn analytics into actual policy outcomes.
The application of AI technology is part of a carefully orchestrated effort dependent on human intelligence, and the collaboration of physicians, disease-specific specialists, nurses, data scientists, and technologists. Done right, these efforts can lead to profound benefits, and offer a promising future for clinical research and patient care.
The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.
PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar.